Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-23

Quarterly was really nice to read, goes to show that there are significant advancements going on behind the scenes.

IHL-675 stage 2 trials to commence next year which in my opinion could be a real honey hole!!!!
Revenue potential looks amazing at $22,000 treatment, with clinics looking to adopt and adapt to a new age of treatment, and IHL is in the best position to cash in.

As with everything, good things take time. The risk-reward scenario is looking better positioned for the way the market is trading. If people want to throw their shares away I will be more than happy to take them off their hands.
In the short term, she is becoming a bit easier to trade to make a few bucks coming into Christmas. Swings of 6-10% are becoming easier to identify if you are that way inclined.